These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. 2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer. Chen Y; Pullambhatla M; Foss CA; Byun Y; Nimmagadda S; Senthamizhchelvan S; Sgouros G; Mease RC; Pomper MG Clin Cancer Res; 2011 Dec; 17(24):7645-53. PubMed ID: 22042970 [TBL] [Abstract][Full Text] [Related]
3. Synthesis and pre-clinical evaluation of a new class of high-affinity Kelly J; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Ponnala S; Babich JW Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):647-661. PubMed ID: 27847991 [TBL] [Abstract][Full Text] [Related]
4. Development of Potemkin R; Strauch B; Kuwert T; Prante O; Maschauer S Mol Pharm; 2020 Mar; 17(3):933-943. PubMed ID: 32011889 [TBL] [Abstract][Full Text] [Related]
5. Synthesis and Biologic Evaluation of Novel 18F-Labeled Probes Targeting Prostate-Specific Membrane Antigen for PET of Prostate Cancer. Harada N; Kimura H; Onoe S; Watanabe H; Matsuoka D; Arimitsu K; Ono M; Saji H J Nucl Med; 2016 Dec; 57(12):1978-1984. PubMed ID: 27417647 [TBL] [Abstract][Full Text] [Related]
6. Tumor Uptake of Triazine Dendrimers Decorated with Four, Sixteen, and Sixty-Four PSMA-Targeted Ligands: Passive versus Active Tumor Targeting. Lim J; Guan B; Nham K; Hao G; Sun X; Simanek EE Biomolecules; 2019 Aug; 9(9):. PubMed ID: 31466360 [TBL] [Abstract][Full Text] [Related]
7. Lee BS; Chu SY; Jung WJ; Jeong HJ; Lee K; Kim MH; Kim MH; Chi DY; Ahn H; Lee YJ; Lee KC; Lim SM Prostate; 2020 Dec; 80(16):1383-1393. PubMed ID: 32960990 [TBL] [Abstract][Full Text] [Related]
8. Brush border enzyme-cleavable linkers: Evaluation for reducing renal uptake of radiolabeled prostate-specific membrane antigen inhibitors. Vaidyanathan G; Kang CM; McDougald D; Minn I; Brummet M; Pomper MG; Zalutsky MR Nucl Med Biol; 2018; 62-63():18-30. PubMed ID: 29803076 [TBL] [Abstract][Full Text] [Related]
9. Targeting Prostate-Specific Membrane Antigen (PSMA) with F-18-Labeled Compounds: the Influence of Prosthetic Groups on Tumor Uptake and Clearance Profile. Bouvet V; Wuest M; Bailey JJ; Bergman C; Janzen N; Valliant JF; Wuest F Mol Imaging Biol; 2017 Dec; 19(6):923-932. PubMed ID: 28639122 [TBL] [Abstract][Full Text] [Related]
11. A high-affinity [(18)F]-labeled phosphoramidate peptidomimetic PSMA-targeted inhibitor for PET imaging of prostate cancer. Ganguly T; Dannoon S; Hopkins MR; Murphy S; Cahaya H; Blecha JE; Jivan S; Drake CR; Barinka C; Jones EF; VanBrocklin HF; Berkman CE Nucl Med Biol; 2015 Oct; 42(10):780-7. PubMed ID: 26169882 [TBL] [Abstract][Full Text] [Related]
12. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer. Benešová M; Schäfer M; Bauder-Wüst U; Afshar-Oromieh A; Kratochwil C; Mier W; Haberkorn U; Kopka K; Eder M J Nucl Med; 2015 Jun; 56(6):914-20. PubMed ID: 25883127 [TBL] [Abstract][Full Text] [Related]
13. Effects of Linker Modification on Tumor-to-Kidney Contrast of Kuo HT; Pan J; Zhang Z; Lau J; Merkens H; Zhang C; Colpo N; Lin KS; Bénard F Mol Pharm; 2018 Aug; 15(8):3502-3511. PubMed ID: 29920108 [No Abstract] [Full Text] [Related]
14. Preclinical evaluation of 86Y-labeled inhibitors of prostate-specific membrane antigen for dosimetry estimates. Banerjee SR; Foss CA; Pullambhatla M; Wang Y; Srinivasan S; Hobbs RF; Baidoo KE; Brechbiel MW; Nimmagadda S; Mease RC; Sgouros G; Pomper MG J Nucl Med; 2015 Apr; 56(4):628-34. PubMed ID: 25722448 [TBL] [Abstract][Full Text] [Related]
15. A PSMA Ligand Labeled with Cobalt-55 for PET Imaging of Prostate Cancer. Dam JH; Olsen BB; Baun C; Høilund-Carlsen PF; Thisgaard H Mol Imaging Biol; 2017 Dec; 19(6):915-922. PubMed ID: 28924629 [TBL] [Abstract][Full Text] [Related]
18. A PSMA-targeted theranostic agent for photodynamic therapy. Chen Y; Chatterjee S; Lisok A; Minn I; Pullambhatla M; Wharram B; Wang Y; Jin J; Bhujwalla ZM; Nimmagadda S; Mease RC; Pomper MG J Photochem Photobiol B; 2017 Feb; 167():111-116. PubMed ID: 28063300 [TBL] [Abstract][Full Text] [Related]
19. In Vitro and In Vivo Characterization of an Lütje S; Franssen GM; Herrmann K; Boerman OC; Rijpkema M; Gotthardt M; Heskamp S J Nucl Med; 2019 Jul; 60(7):1017-1022. PubMed ID: 30655329 [TBL] [Abstract][Full Text] [Related]
20. Single Chelator-Minibody Theranostic Agents for Ho KV; Tatum DS; Watkinson L; Carmack T; Jia F; Mascioni A; Maitz CA; Magda D; Anderson CJ J Nucl Med; 2024 Sep; 65(9):1435-1442. PubMed ID: 39142831 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]